AZUR-4 trial compares neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone

AZUR-4 trial compares neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone — Clinical Colorectal Cancer

This phase II randomized study (AZUR-4) is comparing dostarlimab plus CAPEOX versus CAPEOX alone as neoadjuvant treatment in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer. The trial tests whether adding immunotherapy before surgery improves outcomes in tumors that typically don't respond to immunotherapy.